Munich Reinsurance Co Stock Corp in Munich Decreases Position in Insulet Corporation $PODD

Munich Reinsurance Co Stock Corp in Munich trimmed its holdings in Insulet Corporation (NASDAQ:PODD) by 20.4% in the first quarter, HoldingsChannel.com reports. The firm owned 16,084 shares of the medical instruments supplier’s stock after selling 4,134 shares during the quarter. Munich Reinsurance Co Stock Corp in Munich’s holdings in Insulet were worth $3,375,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Larson Financial Group LLC boosted its holdings in shares of Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. purchased a new stake in Insulet in the fourth quarter valued at $26,000. Elyxium Wealth LLC acquired a new position in Insulet in the fourth quarter valued at $28,000. DV Equities LLC purchased a new position in shares of Insulet during the fourth quarter worth about $28,000. Finally, MV Capital Management Inc. acquired a new stake in shares of Insulet during the fourth quarter worth about $29,000.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet launched Omnipod 5 in Spain, expanding its commercial footprint to a 20th country and adding Omnipod Discover to support digital diabetes care. Article: Insulet Broadens Omnipod 5 Presence With Commercial Launch in Spain
• Neutral Sentiment: Several analyst and commentary pieces noted Insulet’s growth potential from Omnipod 5 and its history of earnings beats, though they also flagged competition and margin pressures. Article: Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
• Negative Sentiment: A new class action and multiple follow-up investor alerts accuse Insulet of making misleading statements about manufacturing quality and undisclosed production problems that allegedly led to medical device corrections affecting millions of pods. Article: Levi & Korsinsky Reminds Insulet Corporation Investors of the Pending Class Action Lawsuit
• Negative Sentiment: Additional law firms filed or publicized securities-fraud claims against Insulet, keeping legal risk in focus and likely weighing on sentiment. Article: Pomerantz Law Firm Announces the Filing of a Class Action Against Insulet Corporation and Certain Officers
• Negative Sentiment: More investor notices reminded shareholders of the August 31 deadline to join or lead the lawsuit, signaling that the litigation story is still developing. Article: Deadline Approaching: Insulet Corporation Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

Insider Activity at Insulet

In other Insulet news, Director Timothy C. Stonesifer acquired 2,790 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The stock was acquired at an average cost of $143.51 per share, with a total value of $400,392.90. Following the purchase, the director directly owned 9,041 shares in the company, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 0.36% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

PODD has been the topic of a number of recent research reports. Wall Street Zen lowered shares of Insulet from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 27th. Leerink Partners cut their target price on Insulet from $360.00 to $247.00 in a research note on Thursday, May 7th. William Blair initiated coverage on Insulet in a report on Wednesday, May 20th. They set an “outperform” rating on the stock. Robert W. Baird cut their price objective on Insulet from $360.00 to $248.00 in a research report on Thursday, May 7th. Finally, Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 target price (down from $380.00) on shares of Insulet in a report on Friday, April 24th. Twenty-two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $238.12.

Insulet Stock Down 2.5%

PODD opened at $157.46 on Thursday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. The company has a market cap of $10.91 billion, a price-to-earnings ratio of 36.62, a PEG ratio of 1.13 and a beta of 1.11. Insulet Corporation has a one year low of $138.79 and a one year high of $354.88. The business’s fifty day moving average is $153.40 and its two-hundred day moving average is $212.61.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The business’s revenue was up 33.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Analysts anticipate that Insulet Corporation will post 6.46 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.